Title :

Radiotherapy or autologous stem-cell transplantation for primary cns lymphoma in patients 60 years of age and younger: results of the intergroup anocef-goelams randomized phase ii precis study

Author(s) :

Houillier, Caroline [Auteur]
Taillandier, Luc [Auteur]
Dureau, Sylvain [Auteur]
Lamy, Thierry [Auteur]
Laadhari, Mouna [Auteur]
Chinot, Olivier [Auteur]
Molucon-Chabrot, Cecile [Auteur]
Soubeyran, Pierre [Auteur]
Gressin, Remy [Auteur]
Choquet, Sylvain [Auteur]
Damaj, Gandhi [Auteur]
Thyss, Antoine [Auteur]
Abraham, Julie [Auteur]
Delwail, Vincent [Auteur]
Gyan, Emmanuel [Auteur]
Sanhes, Laurence [Auteur]
Cornillon, Jerome [Auteur]
Garidi, Reda [Auteur]
Delmer, Alain [Auteur]
Tanguy, Marie-Laure [Auteur]
Al Jijakli, Ahmad [Auteur]
Morel, Pierre [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Bourquard, Pascal [Auteur]
Moles, Marie-Pierre [Auteur]
Chauchet, Adrien [Auteur]
Gastinne, Thomas [Auteur]
Constans, Jean-Marc [Auteur]
Langer, Adriana [Auteur]
Martin, Antoine [Auteur]
Moisson, Patricia [Auteur]
Lacomblez, Lucette [Auteur]
Martin-Duverneuil, Nadine [Auteur]
Delgadillo, Daniel [Auteur]
Turbiez, Isabelle [Auteur]
Feuvret, Loic [Auteur]
Cassoux, Nathalie [Auteur]
Touitou, Valérie [Auteur]
Ricard, Damien [Auteur]
Hoang-Xuan, Khe [Auteur]
Soussain, Carole [Auteur]

Journal title :

Journal of clinical oncology . official journal of the American Society of Clinical Oncology

Abbreviated title :

J. Clin. Oncol.

Pages :

JCO1800306

Publication date :

2019-02-20

ISSN :

1527-7755

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment ...
Show more >OBJECTIVE: To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). METHODS: Immunocompetent patients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as consolidation treatment after induction chemotherapy consisting of two cycles of R-MBVP (rituximab 375 mg/m2222222 RESULTS: Between October 2008 and February 2014, 140 patients were recruited from 23 French centers. Both WBRT and ASCT met the predetermined threshold (among the first 38 patients in each group, at least 24 patients were alive and disease free at 2 years). The 2-year progression-free survival rates were 63% (95% CI, 49% to 81%) and 87% (95% CI, 77% to 98%) in the WBRT and ASCT arms, respectively. Toxicity deaths were recorded in one and five patients after WBRT and ASCT, respectively. Cognitive impairment was observed after WBRT, whereas cognitive functions were preserved or improved after ASCT. CONCLUSIONS: WBRT and ASCT are effective consolidation treatments for patients with PCNSL who are 60 years of age and younger. The efficacy end points tended to favor the ASCT arm. The specific risk of each procedure should be considered.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T16:50:26Z